Finnish M&A deal value rose 20% despite unchanged transaction volumes

Finland completed 579 M&A transactions in 2025 (virtually unchanged from 580 in 2024) while aggregate deal value rose ~20% to an estimated EUR 12.5bn from EUR 10.5bn, remaining below the 2023 peak of EUR 17.8bn. Activity was concentrated in large, strategic deals—notably Hellman & Friedman’s investment in Mehiläinen, Tietoevry’s Tech Services carve-out (Vivicta) and infrastructure consolidation via Lohkare Infra—reflecting buyer focus on profitability and cash-flow resilience amid weak macro conditions (GDP growth 0.2–0.5% and unemployment >10%) and significant private equity dry powder positioning for a recovery.

Analysis

Market structure: The 20% rise in Finnish deal value to ~EUR 12.5bn despite flat volumes signals capital concentration into large, cash‑generative sectors — healthcare, care services and infrastructure — where predictable EBITDA and scale drive bid competition. Winners are platform builders, listed PE and strong balance‑sheet contractors; losers are small, cyclical SMEs and marginal tech services without clear strategic fit. Expect M&A multiples to compress for non-core assets and expand 10–20% for defensible care/infrastructure assets over 12–24 months.

Risk assessment: Key tail risks include a sharper Finnish recession (GDP turning negative, unemployment >11.5%) that stalls exits, and regulatory scrutiny of large private equity healthcare deals (possible price caps or service mandates). Short window (days–weeks): deal rumor volatility; medium (3–9 months): pricing reset if unemployment fails to fall; long (12–36 months): re‑acceleration if dry powder is deployed—monitor private equity dry powder levels and unemployment >10% or <9% thresholds.

Trade implications: Favor credit and equity exposure to large, cash‑flowing healthcare and infrastructure platforms while avoiding small-cap cyclical services. Use relative trades where consolidation tailwinds favour platform owners over fragmented peers; prefer senior secured credit and 3–7y maturities yielding a 150–300bp pickup to Bunds. Option overlays should protect cyclicals into macro data releases (GDP, unemployment).

Contrarian angles: Consensus underestimates carve‑out upside (Tietoevry/Vivicta-style) where standalone entities can re‑rate 20–40% post-separation; conversely the market may be underpricing policy/regulatory risk in healthcare. Historical parallels: Nordic consolidation cycles (post‑2012) show outsized returns for platform owners and listed PE in first 12 months after re‑acceleration. Watch unintended consequence: aggressive bidding for care assets can invite tighter regulation that compresses long‑term IRR.

Key Decisions for Investors

• Establish a 2–3% long position in listed private‑equity exposure EQT AB (EQT.ST) over 6–12 months via a 12‑month call spread (buy 0–20% ITM call, sell 40% OTM call) to capture upside from redeployment of dry powder into Finnish/Nordic buyouts; size per portfolio risk limits and cut at 20% drawdown.
• Allocate 1–1.5% of portfolio to 3–7y senior bonds of large Nordic healthcare/care operators (select bonds with investment‑grade or BB+ equivalent) targeting a spread pick‑up of ≥150bps vs Bunds; sell into rallies if spreads tighten >75bps from entry.
• Implement a relative value pair: long YIT Oyj (YIT.HE) 1.5% vs short SRV Group (SRV.HE) 1.0% — rationale: consolidation benefits established platform (YIT) while SRV faces margin/contract risk; enter on pullback >5% or after confirmation of another platform M&A, target 3–9 month horizon.
• Buy 6‑month protective put spreads on Finnish/cyclical construction exposure (e.g., 10%/20% put spread funded by selling 2% OTM calls) to limit downside if unemployment rises >11% or QGDP turns negative; reassess after next two monthly unemployment prints.